Cynthia X. Ma, MD, PhD, on Metastatic Breast Cancer: Early Results on Copanlisib, Fulvestrant, and Abemaciclib

January 02, 2024 By The ASCO Post Staff

Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, discusses phase I findings showing the safety and tolerability of copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer. Preliminary antitumor activity, which was observed, will be further examined in the phase II trial (ClinicalTrials.gov identifier NCT03939897) (Abstract PS17-06).

Related Content